

# ACC Highlights 2024



**RECORDED LIVE ON:  
MONDAY, APRIL 15, 2024**

This program is intended for cardiovascular specialists and primary care physicians from across Canada.



Developed by:



## ACC Highlights 2024

### FACULTY



#### Milan Gupta

MD, FRCPC, FCCS, CPC(HC)  
Assistant Professor, Department of Medicine, University of Toronto  
Medical Director, Canadian Collaborative Research Network  
Brampton, ON



#### Narendra Singh

MD, FRCPC, FCCS, FACC, FAHA  
Director, NSC Cardiology  
Clinical Assistant Professor,  
Medical College of Georgia at  
Augusta University and Mercer  
University  
Atlanta, GA

This program will cover the key clinical trial findings and their implications from ACC 2024. This program is intended for cardiovascular specialists and primary care physicians.

### Discussion Topics:

- **IMPACT-MI** – Does empagliflozin improve outcomes after acute MI?
- **VICTORION-INITIATE** – Comparing inclisiran first to usual care in patients with ASCVD
- **STEP-HFpEF DM** – What is the role of semaglutide for patients with diabetes and HFpEF?
- **TACT2** – Does chelation reduce events in diabetic post-MI patients?
- **REDUCE-AMI** – Do beta-blockers impact outcome following acute MI with preserved EF?

### Learning Objectives:

Following participation in this program, participants will be able to:

- Review trials and data presented at ACC 2024
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice

This program was developed by CCRN and received an unrestricted educational grant from Novartis



**Watch the recording on  
CCRN [Here](#)**

